Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Medulloblastoma 3Colonic Neoplasms 3Turcot syndrome 2Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Recurrence 2Pinealoma 2Neuroblastoma 2Ependymoma 2Carcinoma 2Urinary Bladder Neoplasms 1Solid Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Osteosarcoma 1Oropharyngeal Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Mouth Neoplasms 1Melanoma 1Locally Advanced Rectal Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Capecitabine 6Oxaliplatin 5camrelizumab 2Radiation 2Irinotecan 2toripalimab 1tislelizumab 1spartalizumab 1sintilimab 1Radiotherapy, Intensity-Modulated 1Leucovorin 1Immune Checkpoint Inhibitors 1Folfox protocol 1Fluorouracil 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Rectal Cancer × Celecoxib × 1 year × Clear all
NCT07150949 2025-09-02

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Fudan University

Phase 2 Recruiting
138 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡